Transgenic fat-1 mouse as a model to study the pathophysiology of cardiovascular, neurological and psychiatric disorders

Polyunsaturated fatty acids (PUFAs) form an important constituent of all the cell membranes in the body. PUFAs such as arachidonic acid (AA), eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) form precursors to both pro-inflammatory and anti-inflammatory compounds. Low-grade systemic inflammation occurs in clinical conditions such as insulin resistance, hypertension, type 2 diabetes mellitus, atherosclerosis, coronary heart disease, lupus, schizophrenia, Alzheimer's disease, and other dementias, cancer and non-alcoholic fatty liver disease (NAFLD) that are also characterized by an alteration in the metabolism of essential fatty acids in the form of excess production of pro-inflammatory eicosanoids and possibly, decreased synthesis and release of anti-inflammatory lipoxins, resolvins, protectins and maresins. We propose that low-grade systemic inflammation observed in these clinical conditions is due to an imbalance in the metabolism of essential fatty acids that is more in favour of pro-inflammatory molecules. In this context, transgenic fat-1 mouse that is designed to convert n-6 to n-3 fatty acids could form an ideal model to study the altered metabolism of essential fatty acids in the above mentioned conditions. It is envisaged that low-grade systemic inflammatory conditions are much less likely in the fat-1 mouse and/or these diseases will run a relatively mild course. Identifying the anti-inflammatory compounds from n-3 fatty acids that suppress low-grade systemic inflammatory conditions and understanding their mechanism(s) of action may lead to newer therapeutic strategies

Microarray technology

The normal functions of the cells are based on a strict and regulated expression of various genes. If this precise hierarchy of gene actions becomes unregulated or disturbed due to different genetic or environmental effects, the result will be abnormal cellular function that eventually could lead pathological alterations, including carcinogenic transformation or apoptosis. To understand the complex mechanisms and networks involved in biological processes and diseases, it is not enough to analyze isolated pathways, single gene functions or a single genetic event. A living organism has to be studied as a complex system and all genes involved in different biological processes need to be analyzed simultaneously: a systems biology approach should be applied. In the beginning of the 1990’s years, a new, high throughput technology - called microarray technology – was developed to measure the expression levels of large numbers of genes simultaneously or to genotype multiple regions of a genome. Microarrays have dramatically accelerated many types of investigation since a microarray experiment can accomplish many genetic tests in parallel. This review summarizes some of aspects of the microarray technology, including sample preparations, application possibilities and data analysis

Combination of small molecule microarray and confocal microscopy techniques for live cell staining fluorescent dye discovery

Discovering new fluorochromes is significantly advanced by high-throughput screening (HTS) methods. In the present study a combination of small molecule microarray (SMM) prescreening and confocal laser scanning microscopy (CLSM) was developed in order to discover novel cell staining fluorescent dyes. Compounds with high native fluorescence were selected from a 14,585-member library and further tested on living cells under the microscope. Eleven compartment- specific, cell-permeable (or plasma membrane-targeted) fluorochromes were identified. Their cytotoxicity was tested and found that between 1-10 micromolar range, they were non-toxic even during long-term incubations. © 2013 by the authors; licensee MDPI, Basel, Switzerland

MicroRNA profile of polyunsaturated fatty acid treated glioma cells reveal apoptosis-specific expression changes

<p>Abstract</p> <p>Background</p> <p>Polyunsaturated fatty acids (PUFAs) such as γ-linolenic acid (GLA), arachidonic acid (AA) and docosahexaenoic acid (DHA) have cytotoxic action on glioma cells.</p> <p>Results</p> <p>We evaluated the cytotoxic action of GLA, AA and DHA on glioma cells with specific reference to the expression of miRNAs. Relative expression of miRNAs were assessed by using high throughput nanocapillary real-time PCR. Most of the miRNA target genes that showed altered expression could be classified as apoptotic genes and were up-regulated by PUFA or temozolomide treatment, while similar treatments resulted in repression of the corresponding mRNAs, such as <it>cox2</it>, <it>irs1</it>, <it>irs2</it>, <it>ccnd1</it>, <it>itgb3</it>, <it>bcl2</it>, <it>sirt1</it>, <it>tp53inp1 </it>and <it>k-ras</it>.</p> <p>Conclusions</p> <p><it>Our </it>results highlight involvement of miRNAs in the induction of apoptosis in glioma cells by fatty acids and temozolomide.</p

Polyploid Adipose Stem Cells Shift the Balance of IGF1/IGFBP2 to Promote the Growth of Breast Cancer

Background: The close proximity of adipose tissue and mammary epithelium predispose involvement of adipose cells in breast cancer development. Adipose-tissue stem cells (ASCs) contribute to tumor stroma and promote growth of cancer cells. In our previous study, we have shown that murine ASCs, which undergo polyploidization during their prolonged in vitro culturing, enhanced the proliferation of 4T1 murine breast cancer cells in IGF1 dependent manner. Aims: In the present study, our aim was to clarify the regulation of ASC-derived IGF1. Methods: 4T1 murine breast carcinoma cells were co-transplanted with visceral fat-derived ASCs (vASC) or with the polyploid ASC.B6 cell line into female BALB/c mice and tumor growth and lung metastasis were monitored. The conditioned media of vASCs and ASC.B6 cells were subjected to LC-MS/MS analysis and the production of IGFBP2 was verified by Western blotting. The regulatory effect was examined by adding recombinant IGFBP2 to the co-culture of ASC.B6 and 4T1. Akt/protein kinase B (PKB) activation was detected by Western blotting. Results: Polyploid ASCs promoted the tumor growth and metastasis more potently than vASCs with normal karyotype. vASCs produced the IGF1 regulator IGFBP2, which inhibited proliferation of 4T1 cells. Downregulation of IGFBP2 by polyploidization of ASCs and enhanced secretion of IGF1 allowed survival signaling in 4T1 cells, leading to Akt phosphorylation. Conclusions: Our results implicate that ASCs in the tumor microenvironment actively regulate the growth of breast cancer cells through the IGF/IGFBP system

HIGH DIMENSIONAL CHARACTERISATION OF CELLULAR FEATURES BY SINGLE CELL MASS CYTOMETRY

High resolution measurement characterizing the large number of cellular features is in the focus of recent cell biological research. To achieve these goals single cell mass cytometry combines advantages of the single cell resolution of traditional fluorescence-based flow cytometry with the multiplexicity of inductively coupled plasma-mass spectrometry. Instead of fluorophores detection for mass cytometry is based on stable heavy-metal isotope labeled antibodies. Thus, the autofluorescence and spectral overlapping are eliminated. The current state-of-the-art mass cytometer is capable of measuring up to 135 different stable isotopes of rare earth metals, although the current availability of these tags in high purity limits the usage to around 45 different rare earth metal tags. This unique feature enables researchers to multiplex up to 45 different antibodies in one single tube. Extensive mapping of signaling networks in single cells, cell surface receptor quantification has been also achieved by single cell mass cytometry. Sample multiplexing is also possible by barcoding prior the antibody labeling which enables the combination of 20 different samples in one single tube. Cell types, cellular populations of interest can be visualized on dot plots and the protein expression levels are demonstrated by histograms. Furthermore, gating hierarchy above 10-12 level is also manageable. Mass cytometry deeply reveals cellular heterogeneity on the basis of highly multiplex phenotypical and functional characterization. There are several novel algorithmic approaches to process large datasets such as: SPADE, viSNE, Citrus. The monitoring of the complex immunophenotype is highly relevant in several human diseases which have been previously restricted to limited number of markers with flow cytometry compared to single cell mass cytometry. Human systemic autoimmune diseases (rheumatoid arthritis, systemic lupus erythemathosus and systemic sclerosis) are under investigation. The cellular complexity and functional heterogeneity of solid tumors, inflammatory diseases and animal models (tumor, bone marrow, spleen, lymph nodes) will be also analyzed in our laboratory by single cell mass spectrometry. Funding: GINOP-2.3.2-15-2016-00030 (LGP); János Bolyai Research Scholarship (GJSz, BO/00139/17/8

SMALL MOLECULES DU192, DU283 AND DU325 INDUCE DIFFERENTIATION AND APOPTOSIS OF HUMAN ACUTE PROMYELOCYTIC LEUKEMIA CELLS

Acute myelogenous leukemia (AML) originates from myeloid stem cells or myeloid blasts halted in an immature state during haematopoiesis. AML represents a group of heterogeneous forms of myeloid malignancies with diverse genetic abnormalities and different stages of myeloid differentiation. The human cell line, HL-60 used in this study belongs to a sub-type of AML, namely acute promyelocytic leukemia (APL). Another pathologic condition of myeloid expansion is the ”emergency” granulo-monocytopoiesis in most of the solid malignancies in which, an army of immature myeloid cells leave the bone marrow, called monocytic and granulocytic myeloid-derived suppressor cells (MDSCs). In contrast to AML, MDSCs are not malignant cells, but promote angiogensesis and immunosuppression leading to the progression of cancer. Both in AML and in solid malignancies the differentiation of immature myeloid cells is an already established therapeutic concept. Since the differentiation of AML cells is frequently followed by apoptosis or increases the sensitivity to chemotherapy, we have screened a library of small molecules to mature the human prototype cells, HL-60. In the resazurin assay small molecules DU192, DU283 and DU325 confounded viability of HL-60 cells, half-inhibitory concentration (IC50) values were as follows: 940 nM, 210 nM and 20 nM, respectively. IC50 could not be determined for human primary fibroblasts in the applied concentration range (1.6 nM - 5 µM). Using flow cytometry we obtained ERK phosphorylation as an early response to DU325 stimulation followed by the increase of the percentage of the Bcl-xl and pAkt bright cells. The expression of the members of the AP-1 TF complex, a driver of cellular differentiation, c-Fos, JunB, c-Jun and JunD were elevated on a concentration and time dependent manner detected by qRT-PCR. As a proof of cellular differentiation the expression of haematopoietic stem cell markers CD33 and CD34 decreased. Due to maturation the size and granularity of HL-60 cells increased upon treatment. Matured myeloid cell marker CD11b elevated on the cell surface detected by flow cytometry. We confirmed that differentiation of HL-60 cells was accompanied by apoptosis. We could detect AnnexinV+/PI- early and AnnexinV+/PI+ late apoptotic populations after 24h of treatment. Caspase-3 activated gradually by time detected by the percentage of active caspase-3 positive cells by flow cytometry and the digestion of zDEVD – amino-Luciferin. Finally, as a proof of massive cell death, we have shown the appearance of the hypo-diploid apoptotic cells in the sub-G1 population and the leakage of the lactate-dehydrogenase into the supernatant. We conclude that DU molecules differentiated immature HL-60 cells, which was followed by apoptosis. We propose to further investigate the effects of DU325 on additional human AML cells obtained from clinical samples. On the other hand we plan to systematically investigate the effect of DU325 on the expansion of immature MDSCs in solid malignancies. Funding: GINOP-2.3.2-15-2016-00030 (LGP); János Bolyai Research Scholarship (GJSz, BO/00139/17/8

Enantioselective Synthesis of 8-Hydroxyquinoline Derivative, Q134 as a Hypoxic Adaptation Inducing Agent

Hypoxia is a common feature of neurodegenerative diseases, including Alzheimer’s disease that may be responsible for disease pathogenesis and progression. Therefore, the hypoxia-inducible factor (HIF)1 system, responsible for hypoxic adaptation, is a potential therapeutic target to combat these diseases by activators of cytoprotective protein induction. We have selected a candidate molecule from our cytoprotective hydroxyquinoline library and developed a novel enantioselective synthesis for the production of its enantiomers. The use of quinidine or quinine as a catalyst enabled the preparation of enantiomer-pure products. We have utilized in vitro assays to evaluate cytoprotective activity, a fluorescence-activated cell sorting (FACS) based assay measuring mitochondrial membrane potential changes, and gene and protein expression analysis. Our data showed that the enantiomers of Q134 showed potent and similar activity in all tested assays. We have concluded that the enantiomers exert their cytoprotective activity via the HIF1 system through HIF1A protein stabilization

Single Cell Mass Cytometry Revealed the Immunomodulatory Effect of Cisplatin Via Downregulation of Splenic CD44+, IL-17A+ MDSCs and Promotion of Circulating IFN-γ+ Myeloid Cells in the 4T1 Metastatic Breast Cancer Model

The treatment of metastatic breast cancer remained a challenge despite the recent breakthrough in the immunotherapy regimens. Here, we addressed the multidimensional immunophenotyping of 4T1 metastatic breast cancer by the state-of-the-art single cell mass cytometry (CyTOF). We determined the dose and time dependent cytotoxicity of cisplatin on 4T1 cells by the xCelligence real-time electronic sensing assay. Cisplatin treatment reduced tumor growth, number of lung metastasis, and the splenomegaly of 4T1 tumor bearing mice. We showed that cisplatin inhibited the tumor stroma formation, the polarization of carcinoma-associated fibroblasts by the diminished proteolytic activity of fibroblast activating protein. The CyTOF analysis revealed the emergence of CD11b+/Gr-1+/CD44+ or CD11b+/Gr-1+/IL-17A+ myeloid-derived suppressor cells (MDSCs) and the absence of B220+ or CD62L+ B-cells, the CD62L+/CD4+ and CD62L+/CD8+ T-cells in the spleen of advanced cancer. We could show the immunomodulatory effect of cisplatin via the suppression of splenic MDSCs and via the promotion of peripheral IFN-γ+ myeloid cells. Our data could support the use of low dose chemotherapy with cisplatin as an immunomodulatory agent for metastatic triple negative breast cancer